Transforming RNA Therapeutics

This chapter explores the evolution of a biotechnology company focused on RNA therapeutics for muscle diseases, detailing its shift from oncology to addressing rare genetic disorders. It highlights funding milestones, including a significant Series C round, and strategic planning for clinical trials aimed at unmet medical needs. The conversation also reflects on the experience of going public during the COVID-19 pandemic, showcasing the challenges and successes of this pivotal transition.